Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC

Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC

While poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have achieved specific clinical benefits in a subset of pancreatic ductal adenocarcinoma (PDAC) patients, the potential role of the PARPi niraparib in PDAC necessitates further exploration. In this study, we demonstrated that Ni...

Full description

Saved in:
Bibliographic Details
Main Authors: Zehui Yao, Huihui Zhang, Kewei Huang, Guizhong Huang, Pu Xi, Lingmin Jiang, Dailei Qin, Fan Chen, Shengping Li, Ran Wei
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Translational Oncology
Subjects:
Pancreatic ductal adenocarcinoma
Niraparib
Autophagy
Gemcitabine-resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523324003334
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1936523324003334

Similar Items